Skip to main content
Patient-Centered Outcomes Research Institute
Patient-Centered Outcomes Research Institute
  • Blog
  • Newsroom
  • Find It Fast
  • Help Center
  • Subscribe
  • Careers
  • Contact Us

PCORI

Patient-Centered Outcomes Research Institute

Search form

  • About Us
    Close mega-menu

    About Us

    • Our Programs
    • Governance
    • Financials and Reports
    • Procurement Opportunities
    • Our Staff
    • Our Vision & Mission
    • Contact Us

    Fact Sheets: Learn More About PCORI

    Download fact sheets about out work, the research we fund, and our programs and initiatives.

    Find It Fast

    Browse through an alphabetical list of frequently accessed and searched terms for information and resources.

    Subscribe to PCORI Email Alerts

    Sign up for weekly emails to stay current on the latest results of our funded projects, and more.

  • Research & Results
    Close mega-menu

    Research & Results

    • Explore Our Portfolio
    • Research Fundamentals
    • Research Results Highlights
    • Putting Evidence to Work
    • Peer Review
    • Evidence Synthesis
    • About Our Research

    Evidence Updates from PCORI-Funded Studies

    These updates capture highlights of findings from systematic reviews and our funded research studies.

    Journal Articles About Our Funded Research

    Browse through a collection of journal publications that provides insights into PCORI-funded work.

    Explore Our Portfolio of Funded Projects

    Find out about projects based on the health conditions they focus on, the state they are in, and if they have results.

  • Topics
    Close mega-menu

    Topics

    • Addressing Disparities
    • Arthritis
    • Asthma
    • Cancer
    • Cardiovascular Disease
    • Children's Health
    • Community Health Workers
    • COVID-19
    • Dementia and Cognitive Impairment
    • Diabetes
    • Kidney Disease
    • Medicaid
    • Men's Health
    • Mental and Behavioral Health
    • Minority Mental Health
    • Multiple Chronic Conditions
    • Multiple Sclerosis
    • Obesity
    • Older Adults' Health
    • Pain Care and Opioids
    • Rare Diseases
    • Rural Health
    • Shared Decision Making
    • Telehealth
    • Transitional Care
    • Veterans Health
    • Women's Health

    Featured Topic: Women's Health

    Learn more about the projects we support on conditions that specifically or more often affect women.

  • Engagement
    Close mega-menu

    Engagement

    • The Value of Engagement
    • Engagement in Health Research Literature Explorer
    • Influencing the Culture of Research
    • Engagement Awards
    • Engagement Resources
    • Engage with Us

    Engagement Tools and Resources for Research

    This searchable peer-to-peer repository includes resources that can inform future work in patient-centered outcomes research.

    Explore Engagement in Health Literature

    This tool enables searching for published articles about engagement in health research.

    Research Fundamentals: A New On-Demand Training

    It enables those new to health research or patient-centered research to learn more about the research process.

  • Funding Opportunities
    Close mega-menu

    Funding Opportunities

    • What & Who We Fund
    • What You Need to Know to Apply
    • Applicant Training
    • Merit Review
    • Awardee Resources
    • Help Center

    PCORI Funding Opportunities

    View and learn about the newly opened funding announcements and the upcoming PFAs in 2021.

    Tips for Submitting a Responsive LOI

    Find out what PCORI looks for in a letter of intent (LOI) along with other helpful tips.

    PCORI Awardee Resources

    These resources can help awardees in complying with the terms and conditions of their contract.

  • Meetings & Events
    Close mega-menu

    Meetings & Events

    • Upcoming
    • Past Events

    January 2021 Board of Governors Meeting

    The Board approved funding for a new research study relating to kidney health and a new funding allocation for PCORnet. Learn more

    Confronting COVID-19: A Webinar Series

    Learn more about the series and access recordings and summary reports of all six sessions.

    2020 PCORI Annual Meeting

    Watch recordings of all sessions, and view titles and descriptions of the posters presented at the virtual meeting.

You are here

  • Research & Results
  • Explore Our Portfolio
  • Comparing the Effects of Different Pr...

This project has results

Comparing the Effects of Different Prostate Cancer Treatments on Quality of Life and Cancer Recurrence -- NC ProCESS

Sign Up for Updates to This Study  

Results Summary and Professional Abstract

Results Summary

Results Summary

Download Summary Español (pdf) Audio Recording (mp3)

What was the research about?

Prostate cancer is the most common type of cancer in men. More than 174,000 men in the United States are diagnosed with it each year. Men with prostate cancer have many treatment options. But the options have different benefits, risks, and side effects. In this study, the research team wanted to learn more about the effects of five treatments:

  • Surgery to remove the prostate
  • External beam radiation therapy, or EBRT, which kills cancer cells with beams of radiation
  • Stereotactic body radiation therapy, or SBRT, which kills cancer cells with strong, focused doses of radiation, limiting damage to healthy tissue
  • Brachytherapy, which places radiation pellets in and near the prostate to kill cancer cells
  • Active surveillance, where the doctor and patient check every few months to make sure the cancer isn’t getting worse

What were the results?

Compared with patients who chose active surveillance, patients who chose

  • Surgery had greater increases in sexual problems and leaking urine at 3, 12, 24, 36, and 48 months.
  • EBRT or brachytherapy had greater increases in sexual problems, trouble urinating, and bowel problems at three months but not at other times.
  • SBRT had less anxiety about prostate cancer at 24 months but not at other times.

Across treatment groups, patients didn’t differ in regret about their treatment decision.

Compared with patients who had surgery, patients who chose SBRT or EBRT had a 51 percent lower chance of prostate cancer coming back.

Compared with patients who chose other treatments, patients who chose active surveillance had, on average per year, more

  • Doctor visits to check on their prostate cancer
  • Total doctor visits
  • Specialist visits

Who was in the study?

The study included 1,413 patients with newly diagnosed prostate cancer in North Carolina between 2011 and 2013. Of these, 71 percent were white, 25 percent were black, and 3 percent were another race. The average age was 64. More than 95 percent of patients had early stage prostate cancer.

What did the research team do?

The research team enrolled patients from the North Carolina Central Cancer Registry. Registries store data about people with a specific health problem. The team surveyed patients by phone before treatment began and again 3, 12, 24, 36, and 48 months later. The surveys asked about patient quality of life, regret about their treatment decision, and anxiety about cancer. Five years after treatment, the team looked at patients’ health records to see if the cancer had come back. They also looked at numbers of doctor visits.

Staff from patient and clinician organizations helped design the study and create study materials.

What were the limits of the study?

Patients chose their treatment, which may have affected their survey responses. The research team didn’t have much information on long-term use of active surveillance, as most patients went on to choose another treatment.

Future research could look at which patients are most likely to benefit from long-term active surveillance.

How can people use the results?

Patients and their doctors can use these results when considering treatment for prostate cancer.

Professional Abstract

Professional Abstract

Objective

To compare the effects of prostate cancer treatments on quality of life, anxiety related to prostate cancer, decisional regret, prostate cancer recurrence, and healthcare utilization

Study Design

Design Element Description
Design Observational: cohort study
Population 1,413 patients with newly diagnosed prostate cancer in North Carolina from 2011–2013
Interventions/
Comparators
  • Active surveillance
  • Radical prostatectomy
  • EBRT
  • SBRT
  • Brachytherapy
Outcomes

Patient-reported quality of life (including sexual, urinary, and bowel function), anxiety related to prostate cancer, and decisional regret; prostate cancer recurrence; healthcare utilization

Timeframe 5-year follow-up for study outcomes

This prospective observational cohort study compared the effects of five treatments for prostate cancer on patient-reported outcomes, prostate cancer recurrence, and healthcare utilization. The treatments were active surveillance, radical prostatectomy, external beam radiation therapy (EBRT), stereotactic body radiation therapy (SBRT), and brachytherapy.

The research team used the North Carolina Central Cancer Registry to recruit patients. To identify patients’ treatments, the team reviewed medical records and cancer registry data. Patients completed phone surveys about quality of life, anxiety related to prostate cancer, and decisional regret before treatment initiation and 3, 12, 24, 36, and 48 months later. The team described clinically meaningful differences between treatments specific to each patient-reported outcome. Five years after treatment, the team reviewed medical records and claims data to determine prostate cancer recurrence and healthcare utilization.

The study included 1,413 patients with newly diagnosed prostate cancer in North Carolina between 2011 and 2013. Of these, 71% were white, 25% were black, and 3% were another race. The average age was 64. More than 95% of patients had stage I or II prostate cancer.

Staff from patient advocacy and clinician professional organizations helped design the study and create study materials.

Results

Compared with patients who chose active surveillance,

  • Patients who chose radical prostatectomy had greater increases in sexual dysfunction and urinary incontinence at 3, 12, 24, 36, and 48 months.
  • Patients who chose EBRT or brachytherapy had greater increases in sexual dysfunction, urinary obstruction, and bowel problems at three months but not at other times.
  • Patients who chose SBRT had lower anxiety about prostate cancer at 24 months but not at other times.

Patients did not differ in decisional regret across treatment groups.

Patients who chose SBRT or EBRT had a 51% decreased risk of prostate cancer recurrence within five years (hazard ratio=0.49) relative to patients who had radical prostatectomy.

Compared with patients who chose other treatments, patients who chose active surveillance had, on average per year, more physician visits related to prostate cancer (6.1 versus 4.6), total physician visits (7.6 versus 6.1), and urology or oncology specialist visits (5.1 versus 4.1).

Limitations

Patients chose their treatment, which may have influenced how they answered surveys. Most patients who chose active surveillance went on to choose another treatment later, which limited data available for patients who used active surveillance for five years.

Conclusions and Relevance

In this study, different treatment strategies were associated with distinct effects on patient quality of life, healthcare utilization, and prostate cancer recurrence. Patients and physicians can use these findings in combination with patients’ expressed preferences to choose a prostate cancer treatment that works best for them.

Future Research Needs

Future research can examine outcomes for patients who continue with active surveillance long term.

Final Research Report

View this project's final research report.

Journal Articles

Results of This Project

European Urology

Patient-reported Quality of Life Following Stereotactic Body Radiotherapy and Conventionally Fractionated External Beam Radiotherapy Compared with Active Surveillance Among Men with Localized Prostate Cancer.

JAMA

Association Between Choice of Radical Prostatectomy, External Beam Radiotherapy, Brachytherapy, or Active Surveillance and Patient-Reported Quality of Life Among Men With Localized Prostate Cancer

Related Articles

Cancer

Patient-reported sexual quality of life after different types of radical prostatectomy and radiotherapy: Analysis of a population-based prospective cohort

Cancer

Factors influencing prostate cancer treatment decisions for African American and white men

Journal of the National Cancer Institute

Prostate Cancer Patient Characteristics Associated With a Strong Preference to Preserve Sexual Function and Receipt of Active Surveillance

More on this Project  

Evidence Updates

Early-Stage and Localized Prostate Cancer
Early-stage prostate cancer can be treated in different ways. Two recent PCORI-funded research studies provide new information on the effects of treatments and can help patients navigate their treatment decisions.

Peer-Review Summary

Peer review of PCORI-funded research helps make sure the report presents complete, balanced, and useful information about the research. It also assesses how the project addressed PCORI’s Methodology Standards. During peer review, experts read a draft report of the research and provide comments about the report. These experts may include a scientist focused on the research topic, a specialist in research methods, a patient or caregiver, and a healthcare professional. These reviewers cannot have conflicts of interest with the study.

The peer reviewers point out where the draft report may need revision. For example, they may suggest ways to improve descriptions of the conduct of the study or to clarify the connection between results and conclusions. Sometimes, awardees revise their draft reports twice or more to address all of the reviewers’ comments. 

Peer reviewers commented and the researchers made changes or provided responses. Those comments and responses included the following:

  • The reviewers asked about the influence of direct-to-consumer advertising on treatment choice for prostate cancer, noting that this could be an important avenue of investigation. The researchers stated that information on the influence of direct-to-consumer advertising is largely anecdotal, but there has been concern that advertisements for some newer therapies may be misleading regarding the advantages of these treatments. The researchers stated that they did not take such advertising into account in this study because understanding the factors associated with treatment selection was not a goal of this study.
  • The reviewers asked about inclusion of hormone therapy, specifically, androgen deprivation therapy (ADT) as a covariate for analyses rather than as one of the compared treatments. The researchers explained that ADT-alone treatment is not guideline recommended, although ADT is acceptable as an adjunct treatment. Therefore, it would not be helpful to measure ADT as an individual treatment.
  • The reviewers asked why the researchers included a small cohort of patients receiving stereotactic body radiation therapy (SBRT) because it is not clear that these patients are comparable to the rest of the North Carolina study participants. The researchers explained that at the time the study started, SBRT was not a common treatment option in North Carolina; however, there was interest in understanding how SBRT compared to other treatment options.  The researchers agreed that the patients receiving SBRT were different from the North Carolina sample, but they collected the same data at the same time points for both groups.
  • The reviewers suggested that aggregating the patient-centered outcomes into a single composite measure might be more meaningful to and useful to patients and their clinicians. The researchers disagreed, saying that it was not clear how a patient would interpret a composite outcome, particularly because two treatments could have similar composite outcomes but vary on individual outcomes. Different patients are likely to put different weights on those individual outcomes and make treatment decisions based on what outcomes are most important to them.

Conflict of Interest Disclosures

The Conflict of Interest Disclosures for this project will be posted here soon. 

Project Details

Principal Investigator
Ronald C. Chen, MD, MPH
Project Status
Completed; PCORI Public and Professional Abstracts, and Final Research Report Posted
Project Title
North Carolina Prostate Cancer Comparative Effectiveness & Survivorship Study (NC ProCESS): A Stakeholder-Driven, Population-Based Prospective Cohort Study
Board Approval Date
September 2014
Project End Date
May 2020
Organization
University of North Carolina at Chapel Hill
Year Awarded
2014
State
North Carolina
Year Completed
2019
Project Type
Research Project
Health Conditions  
Cancer
Prostate Cancer
Intervention Strategies
Screening Interventions
Other Clinical Interventions
Populations
Low Income
Older Adults
Racial/Ethnic Minorities
Funding Announcement
Assessment of Prevention, Diagnosis, and Treatment Options
Project Budget
$1,645,374
DOI - Digital Object Identifier
10.25302/09.2020.CER.131006453
Study Registration Information
HSRP20153204
NCT02564120
Page Last Updated: 
December 2, 2020

About Us

  • Our Programs
  • Governance
  • Financials and Reports
  • Procurement Opportunities
  • Our Staff
  • Our Vision & Mission
  • Contact Us

Research & Results

  • Explore Our Portfolio
  • Research Fundamentals
  • Research Results Highlights
  • Putting Evidence to Work
  • Peer Review
  • Evidence Synthesis
  • About Our Research

Engagement

  • The Value of Engagement
  • Engagement in Health Research Literature Explorer
  • Influencing the Culture of Research
  • Engagement Awards
  • Engagement Resources
  • Engage with Us

Funding Opportunities

  • What & Who We Fund
  • What You Need to Know to Apply
  • Applicant Training
  • Merit Review
  • Awardee Resources
  • Help Center

Meetings & Events

January 21
Cycle 1 2021 Broad PFA Applicant Town Hall
February 2
PCORI 2021 and Beyond: Opportunities for Funding and Involvement in Patient-Centered Research
February 9
Board of Governors Meeting: February 9, 2021

PCORI

Footer contact address

Patient-Centered Outcomes
Research Institute

1828 L Street, NW, Suite 900
Washington, DC 20036
Phone: (202) 827-7700 | Fax: (202) 355-9558
[email protected]

Subscribe to Newsletter

Twitter Facebook LinkedIn Vimeo

© 2011-2021 Patient-Centered Outcomes Research Institute. All Rights Reserved.

Privacy Policy | Terms of Use | Trademark Usage Guidelines | Credits | Help Center